Greenwich LifeSciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.89M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Details
| Name | Greenwich LifeSciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 8 |
| Founded | 2006 |
| Ipo Date | 2020-09-25 |
| Ceo | Snehal Patel |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 5.75 |
| Isin | US3968791083 |
| Cusip | 396879108 |
| Cik | 1799788 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Snehal S. Patel | Chief Executive Officer, Chief Financial Officer and Director |
| Eric Rothe | Founder and Independent Director |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical and Regulatory Affairs |
| Dr. Christine T. Fischette Ph.D. | Vice President of Business Development |
Contact
| Address | Building 14, 3992 Bluebonnet Dr., Stafford, Texas 77477, United States |
| Phone | 832-819-3232 |
| Website | https://greenwichlifesciences.com |